Prospects and perils of retrospective risk assessment of erythropoiesis-stimulating agents.
Steensma
David P
DP
D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006115:Greece / Q000453:epidemiology; D006397:Hematinics / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009101:Multiple Myeloma / Q000150:complications / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D012107:Research Design; D012189:Retrospective Studies; D012306:Risk; D012307:Risk Factors; D015983:Selection Bias; D016019:Survival Analysis; D016896:Treatment Outcome
D006397:Hematinics